Regina Salvat PhD
Principal
Expedition Therapeutics is developing novel treatments for inflammatory and respiratory diseases with the potential to fundamentally transform patient care worldwide.
The therapy is designed to target neutrophilic inflammation, a novel and clinically validated pathway that is a major driver of tissue damage, airway remodeling, and progressive decline in lung function.
The company's lead candidate, EXPD-101, is a potent, oral, once-daily DPP1 inhibitor being developed for COPD, with the potential to deliver continuing improvement for millions of patients who currently have no disease-controlling treatment options.
